List of Personalized Medicine Companies in Israel - 6

Bsense Bio Therapeutics is developing small molecules for the treatment of sensory hyperexcitability related disorders. Bsense is pioneering a novel approach targeting multiple hyperexcitability related mechanisms using a single compound, to achieve greater efficacy and safety. Sensory neuron Hyperexcitability refers to a multitude of indications such as Pain, Pruritus, Tinnitus and seizure, in which sensory neurons are excessively active leading to dire clinical and quality of life ramifications for patients. These indications are considered as significant unmet medical needs representing a major healthcare burden. Bsense Bio's approach is based on the targeting of two cation channels, a ligand-gated cation channel and a voltage-gated potassium channel, respectively, TRPV1 and Kv7.2/3, which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in the modulation of neuronal excitability. The company has generated preclinical proof-of-concept in chronic pain and has recently been generating data in additional hyperexcitability indications in the space of Pruritis and Tinnitus (some of which with Orphan disease designation). The company is financed by Takeda Ventures Inc., OrbiMed Israel Partners, and Johnson & Johnson Innovation (JJDC), RMGP and the Israel Innovation Authority (IIA). Bsense was founded in September 2018 at the FutuRx biotech incubator based on technology that originated from Prof. Bernard Attali and Dr. Asher Peretz work from the Tel Aviv University.

Isotopia is a global leader in innovative radiopharmaceuticals, driving advancements in medical diagnostics and therapeutic solutions. We specialize in developing, producing, and distributing radiopharmaceutical technologies that transform patient care and support medical research globally. Our Comprehensive Radiopharmaceutical Portfolio: Theranostics products: • Lu-177 chloride (non-carrier added and carrier added) Diagnostic and Imaging products: • Isoportrace®- PSMA-11 kit for Ga-68 labeling for prostate cancer imaging Nuclear Pharmacy products: • PET and SPECT products. Global Operations: 1. Israel: • HEADQUARTERS & LU-177 PRODUCTION SITE: Our global headquarters we are dedicated to the production of Lutetium-177 (Lu-177), a critical radionuclide for cancer therapies. This site ensures consistent quality and supply for our global customer base. • ASEPTIC PLANT & CMO SERVICES: Our aseptic plant in Israel specializes in the production of cold kits and offers comprehensive Contract Manufacturing Organization (CMO) services, including the manufacture of sterile and lyophilized products for clinical trials and commercial applications. 2. Austria: GMP-COMPLIANT LU-177 PRODUCTION: Our Austrian facility adheres to Good Manufacturing Practice (GMP) standards, ensuring high-quality production of Lu-177 for therapeutic use, particularly in cancer treatment. 3. United States: LU-177 ISOTOPIA PRODUCTION: Supporting North American operations, this site is focused on producing FDA-compliant Lu-177 Isotopia, meeting the needs of our customers across the region. Our Mission: Isotopia is dedicated to advancing medical breakthroughs with high-quality radiopharmaceuticals that enhance diagnostic accuracy and therapeutic outcomes worldwide. With over 160 professionals and 3 production sites, including 2 in Israel, we ensure a reliable, compliant supply of radiopharmaceuticals globally.

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Utilizing a cloud-based AI platform that performs unbiased, broad-range epiproteomic analyses on standard mass-spectrometry data

Pronto Diagnostics is a leading provider of molecular diagnostic products and services, with extensive knowledge, experience and R&D capabilities in genetic analysis. ProntoLab™, Pronto's molecular services laboratory, has accreditation from the Israel Ministry of Health and ISO 9001:2008 certification. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto Diagnostics has been granted exclusive distribution rights in Israel from leading international molecular diagnostic companies to high quality products and technologies. We are cooperating with the best and most advanced labs in the world such as Centogene, TheragenEtex, Sequenom, MRC-Holland, 10x Genomics, Multiplicom-Agilent, Sophia genetics, DNA Genotek and many more. Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers wherever they may be. For more details please contact our office at : info@prontodiagnostics.com

TargetGene is an innovative and agile biotechnology company in it’s development stage poised for expansion. TargetGene’s R&D is centered around creating efficient and supremely specific DNA editing solutions in living organisms. TargetGene, with it's patented and patent pending "T∙GEE"​ (Genome Editing Engine) platform is the first to invent RNA-guided gene-targeting. TargetGene is aiming to implement the "T∙GEE"​ platform for human gene-therapy with a focus on inherited diseases and cell-based immunotherapy. TargetGene’s platforms include In-Vivo assembling nucleases targeted to the cell's genetic material. Highly specific Targeting is achieved through use of the principle of nucleic acid hybridization. Keywords: Genome editing, Gene Targeting, Genome engineering, Nucleases, RNA-guided Genome Engineering (RGEN), Immunotherapy, Cell-based Therapy, Gene Thearapy, Immuno-oncology. Our new laboratories are situated in the Rehovot Science park, Oppenheimer 10, Rehovot, Israel.